Research offers treatment clues for a high-risk adult leukemia
Ph-like ALL, a high-risk leukemia subtype, is more common in adults than in children. The good news: it may be vulnerable to targeted therapies.
Genetic change reveals precision medicine possibilities for a high-risk leukemia
A possible targeted therapy is found for a high-risk form of acute lymphoblastic leukemia, the most common childhood cancer.
Finding new ways to protect patients during chemo
Newly identified type of lung macrophage protects chemotherapy-treated mice from lethal bacterial pneumonia despite absence of neutrophils.
Editing sickle cell disease
A new gene editing approach eases the effects of sickle cell disease in blood cells isolated from patients.
Most teen survivors of childhood cancer are well adjusted
While most teen cancer survivors are well adjusted, some may benefit from more comprehensive psychological screening to identify and treat symptoms
Chemo drug makes multitasking a challenge for some leukemia survivors
Methotrexate exposure tied to reduced mental flexibility, planning and other executive function skills in long-term survivors of pediatric leukemia.
Child life specialists help young patients get ready for radiation treatment
Child life specialists show support interventions decrease sedation use and cost for radiation therapy.
Applied math and supercomputing help smooth transition from lab to clinic
A modeling approach used lab data to find the optimal drug dose in a successful clinical trial for children with recurrent ependymoma.
Targeted antibiotics may help protect bacterial good guys in the gut
Targeted antibiotic is easier on the gut microbiome; highlights a possible antibiotic drug development strategy
Risk factors found for leukemia treatment complication
Study finds age, ancestry and genetics can influence the risk of pancreatitis, a serious chemo side effect in acute lymphoblastic leukemia patients.
Early success for gene therapy against "bubble boy" disease
Patients with severe combined immunodeficiency (SCID) show unprecedented immune system recovery after receiving gene therapy developed at St. Jude.
Problems in cellular cleanup may contribute to lupus
The most common form of the autoimmune disease lupus may be linked to defects in a cell disposal process called LAP.
Cancer immune therapy: A potential new avenue
T cells do different jobs in the immune system depending on how much c-Myc protein they make, scientists find. What could this mean for immune therapies?
Designing an irresistible flu drug
A promising anti-influenza agent may spark the development of new medicines and combat drug resistance.
Brain infections likely cause different problems before and after birth
Early evidence suggests that infections during pregnancy may alter brain anatomy by driving neuronal proliferation and lead to learning problems.
A new way for cells to kill themselves
When damaged cells don’t die as planned, problems can arise—including cancers. The discovery of a new cell death process may point to new ways to destroy diseased cells.
Insights into improving pneumonia vaccines
One of the deadliest living things on Earth is the pneumococcus bacterium. Insights into how it survives and spreads have profound implications for vaccine strategies.
Diagnosing CNS-PNET tumors: Beyond the microscope
Molecular techniques may beat the microscope for diagnosing CNS-PNET, an aggressive childhood brain tumor.
Parental influence extends to drug response
Researchers demonstrate how differences in inherited genetic makeup can cause problems during leukemia treatment.
Clues to precision treatments for a tough childhood leukemia
Researchers reveal genetic secrets of a high-risk pediatric leukemia called Ph-ALL, and find treatment potential in the drug ruxolitinib.
Understanding how brain tumor treatment affects the brain
An unprecedented study finds that survivors of childhood brain tumors are at risk of memory and intelligence deficits. A key goal? Catch them early.
A promising anti-inflammatory drug tames the immune system
The drug ruxolitinib shows promise in targeting inflammatory reactions in the immune disorder hemophagocytic lymphohistiocytosis (HLH).
Where a brain tumor begins
Research led by a St. Jude scientist has pinpointed likely cells of origin for a common childhood brain tumor, Group 4 medulloblastoma.